SCD

Across TCGA pan-cancer cohorts, SCD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCD data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SCD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCD expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SCD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.590	0.894	.002	19	view →
LUAD	DFS	Tertile	All	0.543	1.000	.004	12	view →
PDAC	OS	Median	All	0.579	0.401	.030	6	view →
LSCC	DFS	Median	II,III,IV	0.963	0.867	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SCD–CCRCC (DFS)

Open the CCRCC breakdown →